If a medication is available in the US but not in your country, read When conventional access fails.
Specialty drug access in India: the named-patient pathway
From first request to drug delivery, a transparent walkthrough of every step.
Last reviewed 2026-05-01 by Reserve Meds clinical & regulatory team. India patients access specialty drugs through a specific regulatory framework documented here.
Why India patients face an access gap in the first place
India's specialty drug market is the largest among Reserve Meds' priority countries by patient volume. The Central Drugs Standard Control Organization (CDSCO), under the Ministry of Health and Family Welfare, regulates drug imports under the Drugs and Cosmetics Act 1940. India has a mature personal-import framework that has supported cross-border access to oncology, rare disease, and pediatric specialty therapies for decades. India also has uniquely strong patient advocacy organizations — particularly for rare diseases — that often co-coordinate with treating physicians on named-patient cases.
Three patterns of access gap apply across India:
- Registered but not stocked. A drug is on the CDSCO list but a particular hospital pharmacy does not have it on hand.
- Registered for a different indication. A drug is registered for one indication but the physician is prescribing it for another FDA-approved use that is not locally registered.
- Not registered locally at all. A drug is FDA-approved in the United States but the manufacturer has not pursued local registration, often because the patient population is small.
The CDSCO (Central Drugs Standard Control Organization) named-patient framework
Under CDSCO's personal-import provisions (Drugs and Cosmetics Rules 1945, Rule 36), a registered medical practitioner in India can request import of a small quantity of an unregistered medicine for a specific patient. The framework is operationalized through the Drugs Controller General of India (DCGI) office. The applicant is typically the treating physician via the institution's import pharmacy. CDSCO requires: clinical justification, license verification, product details, source country regulatory approval evidence, and a chain-of-custody plan.
The application includes:
- Clinical justification letter (diagnosis, severity, prior therapies, why this specific drug)
- Treating physician's local medical license verification
- Patient identifier (anonymized reference preferred)
- Product details: brand name, generic name, manufacturer, strength, quantity
- Destination dispensing facility license
- Chain-of-custody plan from US source to dispensing pharmacy
Approval timelines for routine cases are typically 15-30 business days. Complex cases (rare drug, novel mechanism, off-label use) can extend to 6-12 weeks.
India's private specialty hospital network
The hospitals that handle named-patient imports as established workflow include: Tata Memorial Hospital (Mumbai), Apollo Hospitals (Chennai/Hyderabad/Delhi), Max Healthcare (Delhi), Fortis Healthcare (multiple cities), AIIMS, Medanta, Christian Medical College Vellore. These institutions have import pharmacy infrastructure and physicians experienced with framework applications. If your treating physician is at a smaller institution without import infrastructure, we can help coordinate with one of these centers.
Real costs: what India patients actually pay
Costs vary widely by drug. For context, a 30-day supply of a major specialty oral oncology drug (for example, a kinase inhibitor or BTK inhibitor) typically falls in a USD 6,500-11,500 monthly range for the drug itself, plus international logistics (INR-equivalent of USD 400-1,500 depending on cold chain), plus regulatory documentation handling fees, plus our concierge fee.
For a CAR-T or gene therapy with a list price of USD 400,000-2,000,000, the cost structure changes substantially: the drug dominates everything else. Reserve Meds' role shifts from cost optimization to logistical and regulatory orchestration.
The waitlist form generates an indicative range first, then a transparent firm quote with each line item separated. Nothing is bundled or hidden.
The patient experience: what your family actually does
From the family side, the process looks like this:
- Your physician decides this drug is the right next step. That is a clinical decision and stays with them.
- Your physician (or the hospital's pharmacy team) reaches out to Reserve Meds, or the patient submits the waitlist request and we connect with the physician.
- We confirm eligibility within 24-48 hours and send a documentation kit to your physician.
- Your physician fills out the named-patient application and submits it to CDSCO.
- While the application processes, Reserve Meds aligns the US-side sourcing and shipment plan.
- Approval comes through. We ship cold-chain (or ambient, depending on the drug). Your hospital pharmacy receives the medicine.
- Your physician initiates therapy.
Common India-specific questions
What about the rare disease patient assistance ecosystem in India?
India has uniquely strong patient advocacy organizations, particularly for rare diseases — Lysosomal Storage Disorders Support Society (LSDSS), Organization for Rare Diseases India (ORDI), Sickle Cell Society of India, and disease-specific groups. Many work directly with treating physicians on named-patient cases. The National Policy for Rare Diseases (2021) provides limited financial support for certain orphan drugs at designated Centres of Excellence. Reserve Meds coordinates with patient advocacy organizations when their patient is involved.
What if the drug is a controlled substance?
Reserve Meds does not handle controlled substances (DEA Schedule I-V). Controlled-substance imports require separate regulatory coordination beyond the named-patient framework; we refer those cases to specialists.
Can I receive the drug at home or do I need a hospital?
The dispensing facility must be locally licensed. For oral medicines, a hospital outpatient pharmacy or specialized import pharmacy can dispense. For infusion products, the medicine ships to the infusion center where you will receive it. Direct-to-home delivery without a licensed dispensing facility in the chain is not the model.
What about pediatric patients?
The framework applies the same way for pediatric patients. The clinical justification letter typically includes weight-adjusted dosing and pediatric-specific monitoring requirements. The pediatric oncology and rare disease centers in India handle named-patient imports routinely.
Regional context
India's CDSCO framework is mature but typically slower than GCC frameworks (15-30 business days routine). However, India has a much larger network of private tertiary specialty centers experienced with imports, which often offsets the slower regulator timeline. India also has a robust private health insurance market — Star Health, HDFC Ergo, ICICI Lombard — that occasionally reimburses named-patient imports when the case is well-documented.
Where Reserve Meds fits
Reserve Meds is a US-based concierge coordinator. We do not replace your physician, do not replace CDSCO, do not replace your dispensing pharmacy. What we do is orchestrate the US-side sourcing, the regulatory documentation kit your physician needs, the international logistics, and a single named coordinator throughout your case.
For specialty oncology, rare disease, immunology, neurology, and other specialty therapies, this orchestration is the difference between an unpredictable ad-hoc process and a predictable, documented cycle.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed India physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.
Drug-access guides for India
Each guide below is a named-patient access pathway for that specific drug in India, with real timelines, costs, and the documentation your physician needs. These are coordinated by Reserve Meds for cross-border procurement.